P53-based Cancer Therapy

Overview

Journal Cold Spring Harb Perspect Biol

Specialties Biology
Molecular Biology

Date 2010 May 14

PMID 20463003

Citations 115

Authors

David P Lane

Chit Fang Cheok

Sonia Lain

Affiliations

Soon will be listed here.

Abstract

Inactivation of p53 functions is an almost universal feature of human cancer cells. This has spurred a tremendous effort to develop p53 based cancer therapies. Gene therapy using wild-type p53, delivered by adenovirus vectors, is now in widespread use in China. Other biologic approaches include the development of oncolytic viruses designed to replicate and kill only p53 defective cells and also the development of siRNA and antisense RNA's that activate p53 by inhibiting the function of the negative regulators Mdm2, MdmX, and HPV E6. The altered processing of p53 that occurs in tumor cells can elicit T-cell and B-cell responses to p53 that could be effective in eliminating cancer cells and p53 based vaccines are now in clinical trial. A number of small molecules that directly or indirectly activate the p53 response have also reached the clinic, of which the most advanced are the p53 mdm2 interaction inhibitors. Increased understanding of the p53 response is also allowing the development of powerful drug combinations that may increase the selectivity and safety of chemotherapy, by selective protection of normal cells and tissues.

Citing Articles

Current Development of Therapeutic Vaccines in Lung Cancer.

Flores Banda J, Gangane S, Raza F, Massarelli E Vaccines (Basel). 2025; 13(2).

PMID: 40006732 PMC: 11860707. DOI: 10.3390/vaccines13020185.

Side-stepping the guardian of the genome: current cancer therapeutics targeting mutant p53.

Taritsa I, Fossel E Front Pharmacol. 2025; 16:1529483.

PMID: 39944631 PMC: 11813898. DOI: 10.3389/fphar.2025.1529483.

Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models.

Nguele Meke F, Bai Y, Ruiz-Avila D, Carlock C, Ayub J, Miao J Cancer Res Commun. 2023; 4(1):5-17.

PMID: 38047587 PMC: 10764713. DOI: 10.1158/2767-9764.CRC-23-0308.

p53 stabilisation potentiates [Lu]Lu-DOTATATE treatment in neuroblastoma xenografts.

Berglund H, Salomonsson S, Mohajershojai T, Gago F, Lane D, Nestor M Eur J Nucl Med Mol Imaging. 2023; 51(3):768-778.

PMID: 37823909 PMC: 10796565. DOI: 10.1007/s00259-023-06462-3.

C-C motif chemokine CCL11 is a novel regulator and a potential therapeutic target in non-alcoholic fatty liver disease.

Fan Z, Sun X, Chen X, Liu H, Miao X, Guo Y JHEP Rep. 2023; 5(9):100805.

PMID: 37555008 PMC: 10404559. DOI: 10.1016/j.jhepr.2023.100805.

References

Dey A, Wong E, Cheok C, Tergaonkar V, Lane D . R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ. 2007; 15(2):263-73. DOI: 10.1038/sj.cdd.4402257. View

Kanai M, Hanashiro K, Kim S, Hanai S, Boulares A, Miwa M . Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation. Nat Cell Biol. 2007; 9(10):1175-83. DOI: 10.1038/ncb1638. View

Mayer T, Kapoor T, Haggarty S, King R, Schreiber S, Mitchison T . Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 1999; 286(5441):971-4. DOI: 10.1126/science.286.5441.971. View

Grozinger C, Chao E, Blackwell H, Moazed D, Schreiber S . Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem. 2001; 276(42):38837-43. DOI: 10.1074/jbc.M106779200. View

Brummelkamp T, Fabius A, Mullenders J, Madiredjo M, Velds A, Kerkhoven R . An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol. 2006; 2(4):202-6. DOI: 10.1038/nchembio774. View

Bykov V, Zache N, Stridh H, Westman J, Bergman J, Selivanova G . PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene. 2005; 24(21):3484-91. DOI: 10.1038/sj.onc.1208419. View

van Leeuwen I, Lain S . Sirtuins and p53. Adv Cancer Res. 2009; 102:171-95. DOI: 10.1016/S0065-230X(09)02005-3. View

Shi J, Zheng D . An update on gene therapy in China. Curr Opin Mol Ther. 2009; 11(5):547-53. View

Ventura A, Kirsch D, McLaughlin M, Tuveson D, Grimm J, Lintault L . Restoration of p53 function leads to tumour regression in vivo. Nature. 2007; 445(7128):661-5. DOI: 10.1038/nature05541. View

10.

Stewart D, Ghosh A, Matlashewski G . Involvement of nuclear export in human papillomavirus type 18 E6-mediated ubiquitination and degradation of p53. J Virol. 2005; 79(14):8773-83. PMC: 1168768. DOI: 10.1128/JVI.79.14.8773-8783.2005. View

11.

Oberdoerffer P, Michan S, McVay M, Mostoslavsky R, Vann J, Park S . SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell. 2008; 135(5):907-18. PMC: 2853975. DOI: 10.1016/j.cell.2008.10.025. View

12.

Firestein R, Blander G, Michan S, Oberdoerffer P, Ogino S, Campbell J . The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One. 2008; 3(4):e2020. PMC: 2289879. DOI: 10.1371/journal.pone.0002020. View

13.

Phelan A, Elliott G, OHare P . Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol. 1998; 16(5):440-3. DOI: 10.1038/nbt0598-440. View

14.

Wang Q, Li M, Wang Y, Zhang Y, Jin S, Xie G . RNA interference targeting CML66, a novel tumor antigen, inhibits proliferation, invasion and metastasis of HeLa cells. Cancer Lett. 2008; 269(1):127-38. DOI: 10.1016/j.canlet.2008.04.035. View

15.

FREEDMAN D, Levine A . Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol. 1998; 18(12):7288-93. PMC: 109310. DOI: 10.1128/MCB.18.12.7288. View

16.

Wang R, Sengupta K, Li C, Kim H, Cao L, Xiao C . Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell. 2008; 14(4):312-23. PMC: 2643030. DOI: 10.1016/j.ccr.2008.09.001. View

17.

Bernal F, Tyler A, Korsmeyer S, Walensky L, Verdine G . Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide. J Am Chem Soc. 2007; 129(9):2456-7. PMC: 6333086. DOI: 10.1021/ja0693587. View

18.

Bykov V, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P . Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. 2002; 8(3):282-8. DOI: 10.1038/nm0302-282. View

19.

Joerger A, Ang H, Fersht A . Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci U S A. 2006; 103(41):15056-61. PMC: 1635156. DOI: 10.1073/pnas.0607286103. View

20.

Lavu S, Boss O, Elliott P, Lambert P . Sirtuins--novel therapeutic targets to treat age-associated diseases. Nat Rev Drug Discov. 2008; 7(10):841-53. DOI: 10.1038/nrd2665. View